Key facts
- This page summarizes Matthew Ros's Form 4 filing for Epizyme, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Aug 2021, 08:02.
Matthew Ros - 16 Aug 2021 Form 4 Insider Report for Epizyme, Inc.
- Reporting relationship
- Executive Vice President, Chief Strategy & Business Officer
- Issuer ticker
- N/A
- Reported as of
- 16 Aug 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Aug 2021, 08:02:56 UTC
- Prior SEC filing
- 06 Jul 2021
- Next SEC filing
- 05 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ John Weidenbruch, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Matthew Ros filed Form 4 for Epizyme, Inc. on 18 Aug 2021.
Change
- Previous filing in this sequence was filed on 06 Jul 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EPZM
transaction
Common Stock, par value $0.0001
Award
- Transaction value
- $0
- Shares
- +28,125
- Change %
- +34%
- Price
- $0.000000
- Shares after
- 111,313
- Date
- 16 Aug 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EPZM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +134,178
- Change %
- Price
- $0.000000
- Shares after
- 134,178
- Date
- 16 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 134,178
- Exercise price
- $5.31
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Consists of shares of Common Stock issuable under 28,125 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in three equal annual installments over three years from the grant date, with the first installment vesting on August 16, 2022.
Footnote F2
This option was granted on August 16, 2021 pursuant to the Company's 2013 Stock Incentive Plan with respect to 134,178 shares of Common Stock, with 33.33% vesting on August 16, 2022 and the remaining 66.67% vesting in 24 substantially equal monthly installments thereafter.
SEC remarks
Executive Vice President, Chief Strategy & Business Officer